Literature DB >> 9779132

A comparison of the effects of norepinephrine, epinephrine, and dopamine on cerebral blood flow and oxygen utilisation.

J A Myburgh1, R N Upton, C Grant, A Martinez.   

Abstract

The concomitant effects of infusions of catecholamines on cerebral blood flow (CBF), intracranial pressure (ICP), arterio-venous oxygen content difference (AVDO2), and cerebral oxygen utilization (COU) were prospectively studied in an intact cerebral autoregulatory model. Epinephrine, norepinephrine and dopamine were infused at doses used in clinical practice in awake, chronically catheterized sheep (n = 5). Mean arterial pressure (MAP), CBF and ICP were measured continuously, COU was expressed as delta CBF x AVDO2. All 3 drugs significantly increased MAP in a dose dependent manner. Norepinephrine and epinephrine had no significant effects on ICP, CBF, AVDO2 or COU at infusions of 0-60 micrograms/min. Infusions of dopamine from 0-60 micrograms/kg/min resulted in statistically significant increases in ICP (+34.5 +/- 3.7 to +97.2 +/- 6.8) and CBF (+13.3 +/- 3.2 to +52.6 +/- 24.3) (% change baseline +/- SEM, 95% CI, ANOVA), reduction in AVDO2 (3.54 +/- 0.2. to 2.69 +/- 0.2 mg%) and a biphasic response in COU. In the intact physiological model, induced hypertension by epinephrine and norepinephrine is not associated with global changes in CBF, ICP or COU which remain constant. At equivalent doses, dopamine causes cerebral hyperaemia, increased ICP and increased global cerebral oxygen utilization.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9779132     DOI: 10.1007/978-3-7091-6475-4_6

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  9 in total

1.  The haemodynamic and metabolic effects of epinephrine in experimental hyperdynamic septic shock.

Authors:  David Di Giantomasso; Rinaldo Bellomo; Clive N May
Journal:  Intensive Care Med       Date:  2005-02-15       Impact factor: 17.440

Review 2.  Practical aspects of bedside cerebral hemodynamics monitoring in pediatric TBI.

Authors:  Anthony A Figaji
Journal:  Childs Nerv Syst       Date:  2010-04       Impact factor: 1.475

Review 3.  Hemodynamic management of subarachnoid hemorrhage.

Authors:  Miriam M Treggiari
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

4.  Use and effect of vasopressors after pediatric traumatic brain injury.

Authors:  Jane L Di Gennaro; Christopher D Mack; Amin Malakouti; Jerry J Zimmerman; William Armstead; Monica S Vavilala
Journal:  Dev Neurosci       Date:  2010-12-02       Impact factor: 2.984

5.  Vasopressor Infusion After Subarachnoid Hemorrhage Does Not Increase Regional Cerebral Tissue Oxygenation.

Authors:  Khalil M Yousef; Elizabeth Crago; Yuefang Chang; Theodore F Lagattuta; Khadejah Mahmoud; Lori Shutter; Jeffrey R Balzer; Michael R Pinsky; Robert M Friedlander; Marilyn Hravnak
Journal:  J Neurosci Nurs       Date:  2018-08       Impact factor: 1.230

6.  The effect of infusions of adrenaline, noradrenaline and dopamine on cerebral autoregulation under propofol anaesthesia in an ovine model.

Authors:  John A Myburgh; Richard N Upton; Cliff Grant; Allison Martinez
Journal:  Intensive Care Med       Date:  2003-02-21       Impact factor: 17.440

7.  Norepinephrine and vital organ blood flow during experimental hyperdynamic sepsis.

Authors:  David Di Giantomasso; Clive N May; Rinaldo Bellomo
Journal:  Intensive Care Med       Date:  2003-04-16       Impact factor: 17.440

8.  Effect of cerebral perfusion pressure augmentation with dopamine and norepinephrine on global and focal brain oxygenation after traumatic brain injury.

Authors:  Andrew J Johnston; Luzius A Steiner; Doris A Chatfield; Jonathan P Coles; Peter J Hutchinson; Pippa G Al-Rawi; David K Menon; Arun K Gupta
Journal:  Intensive Care Med       Date:  2004-03-27       Impact factor: 17.440

9.  The cerebrovascular response to norepinephrine: A scoping systematic review of the animal and human literature.

Authors:  Logan Froese; Joshua Dian; Alwyn Gomez; Bertram Unger; Frederick A Zeiler
Journal:  Pharmacol Res Perspect       Date:  2020-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.